| Předmět: |
|
| Zdroj: |
Women's Health Weekly; 3/21/2024, p1416-1416, 1p |
| Abstrakt: |
A recent study conducted at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center has found that immunomodulatory agents, such as DNA methyltransferase inhibitors (DNMTis) and poly (ADP ribose) polymerase inhibitors (PARPi), can activate intracellular antiviral immune responses in cancer cells. The study focused on the role of a little-studied innate immune gene called NFX1-type zinc finger-containing 1 (ZNFX1) in initiating a pathogen mimicry response to DNMTi and PARPi combination treatment. The researchers discovered that ZNFX1 acts as a master regulator for epigenetic reprogramming of mitochondrial inflammasome signaling and pathogen mimicry in cancer cells. This finding suggests a potential avenue for manipulating inflammasome signaling to improve cancer therapy responses and outcomes. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
